Key TPD Insights From ASH 2025
Catch up on the most important targeted protein degradation data presented at ASH 2025 with Beacon’s TPD Post-Conference Report. Our expert analysts reviewed the full programme and identified 255 TPD-relevant abstracts (217 clinical and 38 preclinical), capturing the studies that delivered the most meaningful clinical and translational insights.
The report distils the ASH data into a clear, actionable view of where TPD is demonstrating efficacy, durability, and clinical momentum. It helps you assess how the competitive landscape is evolving, which therapeutic approaches are advancing fastest, and where the field is moving next.
Inside the report, you can expect:
- Late-stage clinical momentum: ~two-thirds of studies report phase 2–3 data
- Disease and modality trends: multiple myeloma, monovalent degraders, and proteasome inhibitors dominate
- Clinical highlights: Golcadomide plus R-CHOP shows 79% PFS, 88% CMR, and 90% MRD negativity
You May Also Be Interested In…
Learn More About TPD
- The Most Comprehensive Way to Search the TPD Drug Development Landscape: Unique search ontologies based on TPD drug and trial characteristics
- Market Leading Approach to TPD Preclinical & Clinical Data Curation: Manual curation of key TPD research and development data points by TPD research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search TPD company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
